Summitplc.com logo

Summit Therapeutics

Summit is committed to leadership in resolving serious, unmet medical needs for the betterment of overall HUMAN HEALTH.

Summit Therapeutics unveiled their INNOVATION ENGINE at the recent 2022 JP Morgan conference highlighting their commitment to BROADER applications across multiple therapeutic areas,
FASTER commercialization through collaboration and acquisitions, and FURTHER changing the focus on human health with new era medicinal therapies for treating disease.

You can view the full 2022 Shareholders Meeting here: Summit Therapeutics 2022 Shareholders Meeting
You can view the full 2022 JP Morgan presentation here: Summit Therapeutics JP Morgan Presentation 2022 

Download the Summit Therapeutics Corporate Brochure

Latest News

We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.

Bob Duggan
Chairman & Chief Executive Officer

Partners

BARDA

Summit is proud to partner with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), as initially announced on September 11, 2017, on its Phase III Ri-CoDIFy trial program investigating ridinilazole for the treatment and reduction of recurrence of C. difficile infection.

CARB-X

Summit is proud to partner with CARB-X, as announced on May 18, 2021, to progress the development of its precision antibiotic candidate, SMT-738, through its IND-enabling and Phase Ia clinical trials for the treatment of highly-resistant CRE bacterial infections.